Merck Stops Development of Parkinson’s Drug


May 24, 2013


Merck & Co. said it will end development of the experimental drug preladenant for Parkinson’s disease because a preliminary review of the data from late-stage clinical trials suggests it doesn’t work.

The drugmaker said it will stop the extension portions of the trials and no longer plans to file for marketing approval of the medicine. Read the full story.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments